The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma.
Lymphoma patients in England are among the first in the world to be offered new CAR T cell therapy.
The National Institute for Health and Care Excellence has recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma.
The National Institute for Health and Care Excellence (NICE) has approved the drug brentuximab vedotin on the NHS in England.
New clinical trial results show that adding rituximab to standard chemotherapy could improve survival for some children with non-Hodgkin lymphoma.
A new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma has not been recommended for NHS use in England.
New ‘chemotherapy-free’ treatment for follicular lymphoma approved for NHS use in England.
A hormone therapy has been approved for NHS use in Scotland for some people with newly diagnosed, advanced prostate cancer for the first time.
A personalised immunotherapy treatment will now be available in Scotland for some adults living with an aggressive form of lymphoma.
People with a certain type of lymphoma will now have access to a targeted cancer drug, called brentuximab vedotin, on the NHS in England.